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Aim. To investigate the combination eﬀects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237
(DPP-IV inhibitor) on prevention against oxidative stress and inﬂammation injury in db/db mice aorta. Methods.D b / d bm i c e
(n = 40) were randomized to receive valsartan, LAF237, valsartan plus LAF237, or saline. Oxidative stress and inﬂammatory
reaction in diabetic mice aorta were examined. Results. Valsartan or LAF237 pretreatment signiﬁcantly increased plasma GLP-1
expression, reduced apoptosis of endothelial cells isolated from diabetic mice aorta. The expression of NAD(P)H oxidase subunits
also signiﬁcantly decreased resulting in decreased superoxide production and ICAM-1 (fold change: valsartan : 7.5 ± 0.7, P<0.05;
LAF237:10.2 ±1.7,P<0.05),VCAM-1(foldchange:valsartan:5.2 ±1.2,P<0.05;LAF237:4.8 ±0.6,P<0.05),andMCP-1(fold
change: valsartan: 3.2 ± 0.6, LAF237: 4.7 ± 0.8; P<0.05) expression. Moreover, the combination treatment with valsartan and
LAF237 resulted in a more signiﬁcant increase of GLP-1 expression. The decrease of the vascular oxidative stress and inﬂammation
reactionwasalsohigherthanmonotherapywithvalsartanorLAF237.Conclusion.Thesedataindicatedthatcombinationtreatment
with LAF237 and valsartan acts in a synergistic manner on vascular oxidative stress and inﬂammation in type 2 diabetic mice.
1.Introduction
Diabetes mellitus is responsible for a host of vascular dete-
rioration such as heart disease, nephropathy, and retinopa-
thy. The key roles that hyperglycemia, inﬂammation, and
oxidative stress play in the progression of diabetes vascular
complications are well recognized. Reactive oxygen species
(ROS), in particular superoxide anion (O2
•−
), have been
shown to initiate several processes involved in diabetes vas-
cular complications, resulting in increased endothelial cells
apoptosis and increased expression of adhesion molecules
which include intracellular adhesion molecule (ICAM)-1,
vascular cell adhesion molecule (VCAM)-1, and mono-
cyte/macrophage chemotactic protein-1 (MCP-1).
Glucagon-like peptide-1 (7–36) amide (GLP-1) is a gut
hormone released postprandially that increases glucose-
stimulated insulin secretion, suppresses glucagon secretion,
and delays gastric emptying [1]. GLP-1 receptors were
expressed in the human pancreas, lung, brain, stomach,
kidney, and heart [2, 3]. It has been shown that GLP-1 could
protect against endothelial dysfunction in type 2 diabetic
patients with coronary heart disease [2, 4, 5]. However,
GLP-1 was not employed for therapeutic use since it is
rapidlyclearedfromthecirculationbytheenzymedipeptidyl
peptidase-IV (DPP-IV). Thus, DPP-IV inhibitor could serve
as a promising potent therapeutic target for diabetic vascular
deterioration. It has been well recognized that angiotensin
II receptor blockers (ARBs) could alleviate endothelial
dysfunction in diabetic patients. However, whether DPP-IV
inhibitor(LAF237)andvalsartanhavesynergisticeﬀectofon
vascular oxidative stress and inﬂammation in type 2 diabetic
mice is still not well understood.
Therefore, the aims of the present study were (1) to
identify the expression of GLP-1 receptor in the diabetic2 Experimental Diabetes Research
mice aorta and the eﬀects of valsartan (angiotensin II type 1
receptor blocker) and LAF237 (DPP-IV inhibitor) on plasma
GLP-1 expression; (2) to investigate the synergistic eﬀect
of valsartan and LAF237 on vascular oxidative stress and
inﬂammation in type 2 diabetic mice.
2.MaterialsandMethods
2.1. Animal Procedures. The experiments were performed in
adherence with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) and were approved
by the Fourth Military Medical University Committee on
Animal Care. Four-week old genetically diabetic C57BL/KSJ
db/db mice and their age-matched nondiabetic littermates
C57/KSJ m/db were obtained from the Laboratory Animal
Services Center of the Fourth Military Medical University.
Db/db mice were randomly divided into four groups: (1)
valsartan-treated (10mg·kg−1·day−1)g r o u p( n = 10) (val),
(2) LAF237-treated (1mg·kg−1·day−1)g r o u p( n = 10)
(LAF), (3) valsartan- and LAF237-combo-treated (valsartan
10mg·kg−1·day−1 + LAF 1mg·kg−1·day−1)g r o u p( n = 10)
(combo), (4) vehicle-treated db/db group (n = 10) (db/db),
and (5) one group of m+/db mice (n = 10) was used as
negative control (m+/db). Mice were treated with valsartan
and LAF237 for 8 weeks. Blood from the tip of the tail
was used to measure blood glucose concentration by using
a reﬂectance meter (Accu-Chek, Roche Diagnostics GmbH,
Mannheim, Germany). Plasma triglycerides, cholesterol,
LDL, and HDL were measured spectrophotometrically by
an automated system (Dade Behring RxL Max). The mice
were fasted overnight before the last day of valsartan or
LAF237 treatment. One hour after the last dose of valsartan
o rL A F 2 3 7w a sg i v e n ,a no r a lg l u c o s et o l e r a n c et e s t( 2g / k g )
was performed. The plasma active GLP-1 was measured with
a commercial assay (Linco Research, St. Charles, MO) 5min
after glucose loading.
2.2. Immunochemistry Staining of GLP-1 Receptor. After
pretreatment with valsartan and LAF237 for 8 weeks, aortas
were isolated from the mice in each group and placed
immediately in ice-cold phosphate-buﬀered saline (PBS).
For immunoperoxidase staining, the ABC staining technique
was applied to illustrate the speciﬁc localization of GLP-
1 receptor in aorta. Aortas were cut into 4mm segments.
T h ea o r t i cs e g m e n t sw e r eﬁ x e di n4 %p a r a f o r m a l d e h y d e
a n de m b e d d e di np a r a ﬃn. Sections of 5μm thickness were
deparaﬃnized and rehydrated through graded alcohols to
water. Endogenous peroxidase was blocked with 3% hydro-
gen peroxide for 20min. After antigen retriever, the sections
were incubated with 6% normal donkey serum for 1 hour
at room temperature to block nonspeciﬁc antibody binding.
The sections were then incubated with anti-GLP-1 receptor
rabbit polyclonal antibody (1:1000) at 4◦C overnight. After
three times washing with PBS, the primary antibody was
detected with the biotinylated secondary antibody from the
Vectastain Elite ABC Kit (rabbit IgG) (Vector Laboratories)
at room temperature for 1h. After another three washes with
PBS, the sections were incubated with the Vectastain Elite
ABC Reagent for 1h at room temperature. The sections were
than washed three times in PBS and incubated in peroxidase
substrate kit DAB (Vector Laboratories) for 7min for brown
color development. Omission of primary antibodies was
used as negative controls. The positive brown staining was
detected under a light microscope equipped with a DFC490
digital camera (Leica Microsystems).
2.3. Determination of Endothelial Cells Apoptosis. After pre-
treatment with valsartan and LAF237 for 8 weeks, aorta
intima was isolated from the mice in each group. Endothelial
cells apoptosis was analyzed by commercially available in
situcelldeathdetectionELISAplusassay(RocheDiagnostics)
according to manufacturer’s instructions. The assay was
repeated for three times to conﬁrm the result. Caspase-3
activity was measured with the ApoAlert Caspase-3 Assay
Plate (Clontech, Mountain View, CA) according to the man-
ufacturer’s protocols [6] .V a l u e sa r ee x p r e s s e da sa r b i t r a r y
units of caspase-3/μg heart tissue.
2.4. Real-Time PCR Analysis. The entire aortas from ﬁve
groups were homogenized, and total RNA was isolated using
Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. The RNA yield was measured by absorbance at
260nm. The ﬁrst strand cDNA was synthesized by Super-
script II reverse transcriptase with oligo(dT)12–18 primer
from 1μg of total RNA. To ensure that the primers were
speciﬁc and eﬃcient, a number of tests were performed.
Quantitative RT-PCR was performed in duplicate using the
following primer sequences: gp91phox, sense 5 -TGC CCA
GTA CCA AAG TTC G-3 , and antisense 5 -TGT CCC ACC
TCC ATC TTG A-3 ;p22phox,sense5 -GTCATGGGGCAG
ATC GAG T-3 , and antisense 5 -AGC ACA CCT GCA GCG
ATA G-3 ; VCAM-1, sense 5 -CGA GGC TGG AAT TAG
CAG A-3 , and antisense 5 -CAT GTT TCG GGC ACA TTT
C-3 ; ICAM-1, sense 5 -GAC CAC GGA GCC AAT TTC T-
3 , and antisense 5 -GTC AGG GGT GTC GAG CTT T-3 ;
MCP-1, sense 5 -AGT TAA CGC CCC ACT CAC C-3 ,a n d
antisense 5 -TGG TTC CGA TCC AGG TTT T-3 ; β-actin,
sense 5 -CTG TAT TCC CCT CCA TCG T-3 , and antisense
5 -GCC ATG TTC AAT GGG GTA CT-3 .
The ampliﬁcation was carried out in 25μLo fr e a c t i o n
mixture containing 12.5μL of SYBR Green Supermix (Bio-
Rad), 1μL of the ﬁrst strand cDNA products, and 3μMe a c h
of the sense and antisense primers. For each set of primers, a
no-templatecontrolwasincluded.Thereactionswerecarried
out on a 96-well plate, and a PCR ampliﬁcation protocol
was followed (95◦C for 5min and 45 cycles of ampliﬁcation
at 95◦C for 30s, 58◦C for 30s, and 72◦C for 30s) using
an iCycler machine (Bio-Rad). Postampliﬁcation melting
curve analysis was performed to show a single ampliﬁcation
product without contamination. Electrophoresis analysis on
a 1.5% agarose gel was also carried out for quality control.
The fold relative to β-actin for the mRNA of interest was
calculated using the 2− ΔΔT method.
cDNA of m+/db mice aorta was synthesized as described
above. RT-PCR was performed in duplicate to detect mRNA
expression of GLP-1 receptor in aorta, using GLP-1 receptorExperimental Diabetes Research 3
primer sequence, sense 5 -CTC TTT GCT ATC GGC GTC
A-3  and antisense 5 -AGC CCT GGA AGG AAG TGA A-
3 . PCR was performed using the following thermal cycle:
5m i n u t e sa t9 4 ◦C, followed by 35 cycles of 30 seconds at
94◦C, 30 seconds at 58◦C, and 1 minute at 72◦C. cDNA
of m+/db mice pancreas was used as positive control. The
PCRproductsweredemonstratedbyelectrophoresison1.5%
agarose gels.
2.5. Localization and Quantiﬁcation of Superoxide Anion.
To assess in situ O2
•−
production, dihydroethidium (DHE)
ﬂuorescence of aortic tissue sections was used. Aortae were
prepared as described above, and 4mm segments were
embedded in a resin (Tissue-Tek O.C.T. 4583 Compound)
and frozen, and stored at −80◦C. Samples were sectioned on
a Leica cryostat (20μm) and placed on glass slides and ﬁxed
with 4% paraformaldehyde for 10min at room temperature.
DMSO containing 2μmol/L DHE was topically applied to
each tissue section, and sections were incubated in a dark,
humidiﬁed chamber at 37◦C for 30 minutes. Omission
of DHE was used as negative controls. DHE (red) and
autoﬂuorescence (green) were detected with a ﬂuorescent
microscope equipped with a DFC490 digital camera (Leica
Microsystems). Computer-based analysis was performed
using Olympus Fluoview ver 1.5 software (Olympus). Data
were expressed as % ﬂuorescence/mm2.
2.6. Immunoﬂuorescence Staining of Monocyte Chemotactic
Protein-1 (MCP-1). Cryosections of aorta were used for
MCP-1 immunoﬂuorescence staining. Sections were pre-
pared as described above and incubated with 6% normal
donkey serum for 1 hour at room temperature to block
nonspeciﬁc antibody binding. The sections were then incu-
bated with anti-MCP-1 rabbit polyclonal antibody (1:100)
(Santa Cruz Biotechnology) at 4◦C overnight. After three
times washes with PBS, the primary antibody was detected
with rhodamine-conjugated donkey anti-rabbit IgG (1:100)
(J a c k s o nI m m u n o R e s e a r c h )f o r1h o u ra tr o o mt e m p e ra t u r e .
Omission of primary antibody was used as negative controls.
MCP-1 (red) immunolabeling was detected with a ﬂuores-
cent microscope equipped with a DFC490 digital camera
(Leica Microsystems).
2.7. Western Blot Assay. Protein was isolated from mice
aorta with Trizol reagent (Invitrogen, Carlsbad, CA) and
standard Invitrogen protocols as previously described [6, 7].
In brief, the Bradford assay (Bio-Rad Laboratories, Hercules,
CA) was used to quantify protein concentrations. Protein
was then used for western blotting with primary antibodies
against GLP-1R. All of the antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, Calif). The blots
were visualized with a chemiluminescence system (Amer-
sham Bioscience, Buchinghamshire, UK). The signals were
quantiﬁed by densitometry.
2.8. Statistical Analysis. Results of quantitative studies were
expressed as means ± SD. Each data point represents the
averageof5to6experiments.Multiplecomparisonsbetween
groups were performed by using an analysis of variance
(ANOVA) followed by Turkey’s post hoc test. Statistical
signiﬁcance was accepted for P v a l u el e s st h a n0 . 0 5 .
3. Results
3.1. Basic Parameters. Blood glucose was signiﬁcantly
decreased in valsartan, LAF237, and combo treatment group
compared with vehicle-treated db/db group. The combi-
nation treatment with valsartan and LAF237 for 8 weeks
signiﬁcantly decreased triglycerides, total cholesterol, and
LDL and increased plasma HDL compared with vehicle-
treated db/db group (Table 1).
3.2. Detection of GLP-1 Receptor (GLP-1R) and the Eﬀects of
Valsartan and LAF237 on Plasma GLP-1 Expression. GLP-
1 receptor expression in diabetic mice aorta was detected
by real-time PCR (RT-PCR), western blot, and immuno-
histochemistry staining. Figures 1(a) illustrated the RT-PCR
products generated from RNA extracted from aorta and
pancreas. GLP-1 receptor mRNA was detectable both in
db/db mice aorta and pancreas. Western blot analysis also
showed that GLP-1R was expressed on db/db mice aorta
(Figures 1(b)). Immunohistochemistry was used to further
determine that GLP-1 receptor was expressed on diabetic
mice aorta (Figures 1(c), 1(d)). Valsartan (5.8 ± 0.6v e r s u s
2.7±0.8,P<0.05)orLAF237(10.4±1.0v e r s u s 2 .7±0.8,P<
0.05) administration signiﬁcantly increased plasma GLP-1
expression compared with the db/db group. Furthermore,
combination treatment with valsartan and LAF237 showed
more eﬀective increase than that of single-treated group
(combo: 14.2 ± 1.1v e r s u sv a l :5 .8 ± 0.6 versus LAF: 10.4 ±
1.0; P<0.05) (Figures 1(e)).
3.3.AntiapoptoticEﬀectsofValsartanandLAF237onEndothe-
lial Cells of Diabetic Mice Aorta. DNA fragmentation in
diabetic mice aorta was detected by in situ cell death ELISA
(Figures 2(a)). The degree of DNA fragmentation was about
9.6 times higher in db/db group compared with m+/db
nondiabetic mice. The level of DNA fragmentation was
signiﬁcantly reduced with the pretreatment of valsartan
(−46%; P<0.05) or LAF237 (−45%; P<0.05). Moreover,
the combined treatment could further reduce endothelial
cells apoptosis (−78%; P<0.05).
Wealsodeterminedlevelsofcaspase-3activityandfound
that valsartan (75.7 ± 8.4 versus 115.0 ± 8.1, P<0.05)
and LAF237 (78.8 ± 10.9 versus 115.0 ± 8.1, P<0.05)
statisticallydecreasedcaspase-3enzymaticactivitycompared
with the db/db group. The combination treatment signiﬁ-
cantly reduced caspase-3 activity compared with valsartan
(44.6±5.3v e r s u s 7 5 .7±8.4,P<0.05)orLAF237(44.6±5.3
versus 78.8±10.9, P<0.05)singletreatment(Figures2(b)).
3.4. Eﬀects of Valsartan and LAF237 on NA(D)PH Oxidase
Subunits of Diabetic Mice Aorta. T h em R N Ae x p r e s s i o no f
the p22phox and gp91phox subunits of NA(D)PH oxidase
was measured by real-time PCR analyses. The expression
of p22phox and gp91phox subunits of NAD(P)H oxidase4 Experimental Diabetes Research
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Figure 1: Detection of GLP-1R and the eﬀects of valsartan and LAF237 on plasma GLP-1 expression. GLP-1R mRNA expression was
measured by RT-PCR. Pancreas was utilized as positive control (a). Western blot analysis showed that GLP-1R was expressed in db/db mice
aorta (b). Negative control of GLP-1 receptor immunostaining (c). GLP-1 receptor was expressed on endothelium of diabetic mice aorta
showed in brown (bar, 50μm) (d). The plasma GLP-1 expression was increased by valsartan or LAF237 pretreatment. The combination
treatment with valsartan and LAF237 showed more eﬀective increase than that of single treated group (e). The columns and errors bars
represent means and SD. ∗P<0.05 versus db/db group, #P<0.05 versus combined treatment group.Experimental Diabetes Research 5
Table 1: Basic parameters in db/db mice and their controls.
Basic parameters m+/db (n = 10) Valsartan
(n = 10)
LAF237
(n = 10)
Combo
(n = 10) db/db (n = 10)
Body mass (g)
4w 17.5 ±1.92 6 .3 ± 2.12 5 .6 ±2.82 4 .1 ±2.22 5 .8 ±3.4
12w 27.5 ±2.9
∗# 41.2 ±4.0# 35.3 ±3.7
∗ 36.4 ±3.9
∗ 40.8 ±4.3
Glucose (mmol/L)
4w 6.3 ±1.2
∗# 8.7 ±1.18 .2 ±1.48 .5 ±0.88 .1 ±1.2
12w 8.2 ±1.4
∗# 22.4 ±2.7# 17.5 ±2.4
∗ 17.8 ±2.2
∗ 25.3 ±3.3
Triglycerides
(mmol/L)
4w 0.65 ±0.07
∗# 1.23 ±0.14 1.21 ±0.18 1.24 ±0.16 1.22 ±0.23
12w 0.70 ±0.05
∗# 1.73 ±0.20 1.65 ±0.18
∗ 1.62 ±0.14
∗ 1.85 ±0.29
Cholesterol (mmol/L)
4w 2.37 ±0.26
∗# 3.70 ±0.32 3.73 ±0.45 3.68 ±0.34 3.71 ±0.41
12w 2.42 ±0.18
∗# 3.46 ±0.32# 3.23 ±0.24
∗ 3.15 ±0.28
∗ 3.52 ±0.38
LDL (mmol/L)
4w 0.96 ±0.03
∗# 1.53 ±0.12 1.55 ±0.17 1.56 ±0.15 1.54 ±0.22
12w 0.92 ±0.04
∗# 1.38 ±0.11
∗ 1.42 ±0.16
∗ 1.37 ±0.16
∗ 1.63 ±0.21
HDL (mmol/L)
4w 1.17 ±0.15
∗# 1.55 ±0.14 1.53 ±0.16 1.56 ±0.18 1.58 ±0.17
12w 1.20 ±0.16
∗# 1.69 ±0.18
∗# 1.83 ±0.25 1.98 ±0.27
∗ 1.73 ±0.14
Values are presented as mean ± SD.
∗P<0.05 versus db/db group, #P<0.05 versus combined treatment group.
was signiﬁcantly increased in db/db mice comparing with
m+/db mice (fold change: p22phox (9.4 ± 1.6) and gp91phox
(5.4 ± 1.5); P<0.05). The expression of p22phox and
gp91phox subunits was signiﬁcantly decreased compared with
db/db mice after treating with valsartan (p22phox −53% and
gp91phox−46%; P<0.05) or LAF237 (p22phox −48% and
gp91phox−57%; P<0.05). The combo-treated group showed
more eﬀective decrease than that of single-treated group
(p22phox −77% and gp91phox−83%; P<0.05) (Figures 2(c),
2(d)).
3.5. In Situ Measurement of O2
•−
Production in Aortic Seg-
ments. Dihydroethidium (DHE, Invitrogen), an oxidative
ﬂuorescent probe, was used to detect in situ oxidative stress.
Morphologic analysis revealed intracellular formation of
O2
•−
in vessel area containing endothelial cells and medial
smooth muscle cells (SMCs) (Figure 3). Quantiﬁcation of
the ﬂuorescent signal showed a signiﬁcant increase of
ﬂuorescence intensity in the aorta of db/db mice compared
with m+/db group (fold change: 2.2 ± 0.4; P<0.05). After
treated with valsartan or LAF237, the ﬂuorescence intensity
was signiﬁcantly decreased (fold change: 1.6 ± 0.3a n d1 .4 ±
0.3; P<0.05) compared with m+/db group. Moreover, the
combo-treated group showed more signiﬁcant decrease than
that of single treated group (fold change: 1.1±0.2; P<0.05)
(Figure 3).
3.6. Eﬀects of Valsartan and LAF237 on Adhesion Molecules
in Diabetic Mice Aorta. To demonstrate MCP-1 expression
on the aorta endothelium, immunoﬂuorescence staining
was performed. Figures 4(a)–4(e) illustrated that MCP-1
was located on db/db aorta endothelium. The intensity of
ﬂuorescence was reduced in valsartan- and LAF237-treated
group. Real-time PCR was used to further conﬁrm the
expression of MCP-1. The mRNA expression of MCP-1 was
increasedindb/dbgroupcomparedwithm+/dbnondiabetic
group (fold change: 9.3 ± 1.1, P<0.05). After treated
with valsartan or LAF237, the expression of MCP-1 was
signiﬁcantly decreased (fold change: 3.2 ± 0.6a n d4 .7 ± 0.8;
P<0.05) compared with m+/db group. The combination-
treated group further decreased MCP-1 expression (fold
change: 1.8 ±0.4, P<0.05) (Figures 4(f)).
The mRNA expression of ICAM-1 (fold change: 18.3 ±
1.9, P<0.05) and VCAM-1 (fold change: 9.6±1.2, P<0.05)
was also signiﬁcantly increased in db/db group compared
with m+/db group. Valsartan and LAF237 pretreatment
signiﬁcantly decreased ICAM-1 (valsartan: 7.5 ± 0.7, P<
0.05; LAF237: 10.2 ± 1.7, P<0.05) and VCAM-1 (valsartan:
5.2 ± 1.2, P<0.05; LAF237: 4.8 ± 0.6, P<0.05) expres-
sion. The combo-treated group showed more signiﬁcant
decrease compared with single-treated group (Figures 4(g),
4(h)).
4. Discussion
Glucagon-like peptide-1 (GLP-1), the most potent insulin-
otropic hormone known, increases glucose-stimulated
insulin secretion, suppresses glucagon secretion and delays
gastric emptying [8, 9]. However, therapeutic use of GLP-16 Experimental Diabetes Research
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Figure 2: Eﬀects of valsartan and LAF237 on apoptosis and NA(D)PH oxidase subunits of endothelial cells of db/db mice aorta. DNA
fragmentation of each group was detected by ELISA. Valsartan and LAF237 pretreatment signiﬁcantly reduced endothelial cells apoptosis.
Thecombinedtreatmentcouldfurtherreduceendothelialcellsapoptosis(a).ValsartanandLAF237signiﬁcantlydecreasedcaspase-3activity
compared with the db/db group (b). The expression of p22phox and gp91phox subunits was signiﬁcantly decreased compared with db/db mice
after treating with valsartan or LAF237. The combo-treated group showed more eﬀectively decrease than that of single treated group (c, d).
The columns and errors bars represent means and SD. ∗P<0.05 versus db/db group, #P<0.05 versus combined treatment group.
itself is severely compromised by its lack of oral activity
and rapid degradation by plasma dipeptidyl peptidase IV
(DPP-IV). Compelling studies have shown that inhibition
of DPP-IV was eﬀective in improving glucose tolerance
in diabetic patients in human clinical trials since DPP-IV
inhibition could extend the duration of GLP-1 action and
prolong its beneﬁcial eﬀects [10, 11]. Therefore, DPP-IV
inhibitor (LAF237) oﬀers a new strategy for treating type
2 diabetes. Several studies have explored the expression
of GLP-1 receptor in pancreatic islet cells, gastrointestinal
tract, heart, lung, and so forth [12]. In the present study,
we also demonstrated that GLP-1 receptor is expressed on
diabetic mice aorta as evidenced by RT-PCR, western blot,
and immunohistochemistry staining.
Endothelial dysfunction can be improved by inhibition
of rennin-angiotensin system using ACEI or ARB, not only
in patients with coronary artery disease, hypertension, and
chronic heart failure, but also in patients with diabetes
[13]. Angiotensin II could interact with oxygen radicals and
stimulatesthegenerationofoxygenradicalsbyincreasingthe
expression of the nicotinamide adenine dinucleotide phos-
phate via activation of the AT1 receptor. Previous studies
indicated that LAF237 (inhibitor of dipeptidyl peptidase
IV) and valsartan (antagonist of the angiotensin II type
1 receptor) have signiﬁcant beneﬁcial additive eﬀects on
pancreatic β-cell structure and function compared with
their respective monotherapeutic eﬀects [14]. The aim of
the present study is to investigate the combination eﬀects
of valsartan and LAF237 on vascular oxidative stress and
inﬂammation in db/db mice.
In the present study, we demonstrated that both of
valsartan and LAF237 increased plasma GLP-1 expression
compared with the vehicle-treated group. Furthermore,
combination treatment with valsartan and LAF237 showed
more eﬀective increase than that of single-treated group.
We also explored the antiapoptotic eﬀects of valsartan and
LAF237 on endothelial cells of diabetic mice aorta. Both
of them reduced endothelial cells apoptosis. Moreover, the
combination therapy of valsartan and LAF237 induced a sig-
niﬁcantly lower apoptosis rate compared with monotherapy.Experimental Diabetes Research 7
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Figure 3: In situ measurement of O2
•−
production in aortic segments. ROS generation within the aorta determined by dihydroethidium
(DHE) ﬂuorescence (×630 magniﬁcation). Fluorescence photomicrographs at identical settings of sections of thoracic aorta labeled with
DHE. Positive staining was shown in red, and green part indicated auto-ﬂuorescence. (a) m+/db mouse aorta; (b) valsartan-treated mouse
aorta; (c) LAF237-treated mouse aorta; (d) combo-treated mouse aorta; (e) nontreated db/db mouse aorta (bar, 10μm). (f) Quantiﬁcation
of the ﬂuorescence signal showed that the ﬂuorescence intensity was signiﬁcantly decreased in valsartan or LAF237 pretreatment group
compared with m+/db group. The columns and errors bars represent means and SD. ∗P<0.05 versus db/db group, #P<0.05 versus
combined treatment group.
Diabetes is associated with an increased risk for vas-
cular deterioration. Endothelial cells regulate basal vascular
tone and vascular reactivity with the release of a variety
of contracting and relaxing factors. It has been shown
that diabetes can cause endothelial cell damage by several
mechanisms, including apoptosis and increased oxidative
stress. Oxidative stress implies a loss of redox homeostasis
with an excess of ROS production by singular process of
oxidation. ROS include free radicals such as superoxide
anion, peroxynitrite, hydroxyl, and H2O2. Loss of the
modulatory role of the endothelium may play a key role in
the development of diabetic vascular dysfunction [15, 16].
Here,weuseddihydroethidiumstainingtolocalizeinsitu
O2
•−
production.DHEisaﬂuorescentdye,whichspeciﬁcally
reacts with intracellular O2
•−
and is converted to the red
ﬂuorescent compound ethidium. DHE red ﬂuorescence was8 Experimental Diabetes Research
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Figure 4: Eﬀects of valsartan and LAF237 on adhesion molecules in db/db mice aorta. Representative images of MCP-1 expression were
shown in Figures 4(a)–4(e). (a) m+/db mice aorta; (b) valsartan-treated mice aorta; (c) LAF237-treated mice aorta; (d) combo-treated mice
aorta; (e) nontreated db/db mouse aorta. The intensity of ﬂuorescence was reduced in valsartan and LAF237-treated group (bar, 25μm).
The mRNA expression of MCP-1(f), ICAM-1(g), and VCAM-1(h) was evaluated by real-time PCR. The columns and errors bars represent
means and SD. ∗P<0.05 versus db/db group, #P<0.05 versus combined treatment group.Experimental Diabetes Research 9
localized mainly in endothelial cells and smooth muscle
layers according to the production proﬁle of O2
•−
within
the arteries. In the present study, we found that ﬂuorescence
intensity in the aorta isolated from nontreated db/db mouse
was about 2 times higher than that of the m+/db mice,
indicating an increase in O2
•−
formation. After treated with
valsartan or LAF237 for 8 weeks, O2
•−
production was
signiﬁcantly decreased. Meanwhile, combo-treated mouse
showed further more reduced O2
•−
formation.
NAD(P)H oxidase, which catalyzes the NADPH-
dependent reduction of oxygen to form superoxide, is one
of the most important sources of superoxide production in
vascular tissue. Vascular NAD(P)H oxidase is a multimeric
protein complex that consists of plasma membrane-bound
subunits (gp91phox/Nox2 and p22phox) and cytosolic
subunits (p40phox, p47phox, p67phox, and small GTPase
Rac1). A strong correlation between p22phox expression and
superoxide production in human coronary artery disease
(CAD) has been reported [17]. NAD(P)H oxidase activity
in CAD was associated with elevated expression levels of
p22phox and gp91phox [18]. Roberts et al. demonstrated
that NAD(P)H oxidases were strongly involved in impaired
vascular function in the thoracic aorta of rats fed a diet
enriched with sugar and fat [19].
In the present study, we have explored the role of
NAD(P)H oxidase gp91phox and p22phox s u b u n i t sa sm o d -
ulators of ROS production in diabetic mice. The mRNA
expression of gp91phox and p22phox subunits of NAD(P)H
oxidase was signiﬁcantly increased in the diabetic mice
aortic. Valsartan and LAF237 pretreatment signiﬁcantly
decreased NAD(P)H oxidase gp91phox and p22phox subunits
expression.ThecombotreatmentwithvalsartanandLAF237
could further reduce the mRNA expression of the above
units, indicating a synergistic eﬀect of valsartan and LAF237
on vascular oxidative stress in diabetic mice.
During the development of diabetes, a number of bio-
chemical and mechanical factors converge on the endothe-
lium, resulting in endothelial dysfunction and vascular
inﬂammation.Theinﬂammatorysiteinendothelialdysfunc-
tion may be where the process of inﬂammation in type 2 dia-
betes begins. An increased adhesion of leukocytes (especially
monocytes) to the endothelium followed by transmigration
into the subendothelial space is a crucial early event in the
pathogenesis of atherosclerosis and certain inﬂammation
disorders. It has been well recognized that increased levels
of ROS activate signal transduction processes leading to
expression of proinﬂammatory cytokines/chemokines such
as TNF-α,I L - 1 β, IL-6, MCP-1, and IL-8, as well as adhesion
molecules such as VCAM-1 and ICAM-1 in endothelial cells,
microglia, and astrocytes [20]. Hyperglycemia could also
increase the expression of ICAM-1, VCAM-1, and MCP-1
release [13, 21, 22].
The present data demonstrated that mRNA expression
of ICAM-1 and VCAM-1 in db/db mouse was much higher
than in m+/db mouse, after treated with valsartan or
LAF237, and the expression of these adhesion molecules
was decreased. Furthermore, the combo treatment induced
a more signiﬁcant decrease compared with the single-treated
group. In db/db mouse, MCP-1 release was signiﬁcantly
increasedasevidencedbystainingwithmonoclonalantibody
against MCP-1 and real-time PCR. The combo treatment
with valsartan and LAF237 also had a more signiﬁcant
decrease of MCP-1 compared with single treatment using
either valsartan or LAF237.
In conclusion, these results indicated that oxidative stress
andinﬂammatoryreactionwereevidentindb/dbmiceaorta.
NADPH oxidase played a pivotal role in ROS production,
resulting in increased expression of adhesion molecules such
as VCAM-1, ICAM-1, and MCP-1. Valsartan or LAF237 sig-
niﬁcantlyreducedoxidativestressandinﬂammatoryreaction
in diabetic mice aorta as evidenced by reduced apoptosis
and reduced expression of NAD(P)H oxidase submits, ROS
production, ICAM-1, VCAM-1, and MCP-1 expression.
Furthermore, LAF237 and valsartan act in a synergistic
manner on vascular oxidative stress and inﬂammation in
type2diabeticmice.Thepossiblemechanismresponsiblefor
the eﬀects of valsartan and LAF237 is associated, at least in
part, with the upregulation of plasma GLP-1 expression.
5. Study Limitations
The present study did not reveal the exact molecular
pathways of valsartan and LAF237 act on. The detailed
mechanism of how valsartan upregulates plasma GLP-1
expression and the mechanism of valsartan and LAF237 on
the diabetic complication remains to be clariﬁed.
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